Not to overlook the important fact that DCB has confirmed that FTO is a key focus for the company. So for some of us who have hazarded a guess that cardio protection vs FTO being a cause of disagreement in the boardroom, this should give us comfort that the dual focus hasn’t changed.
While I am glad breast cancer was prioritised and news released I still wonder why other major cancer types weren’t in scope for this study as I thought the purpose of the study was going to be broad application of cardio protection and not limited to breast cancer. More news to come on this front?
If we can achieve $20Bn USD deal per todays Ann, that it itself will be life changing financially for many of us. Looking forward to how this changes the buy vs sell volumes going forward and the SP reaction.
No advice.
Ann: Race releases cardioprotection market potential data, page-25
-
- There are more pages in this discussion • 216 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
